Pilot Study of a Digital Health Application for Strengthening Self-Management and Adherence to Therapy Guidelines in Patients with Hypertension, Hypertension, and concomitant Chronic Ischemic Heart Disease, and/or Heart Failure

Pilot Study of a Digital Health Application for Strengthening Self-Management and Adherence to Therapy Guidelines in Patients with Hypertension, Hypertension, and concomitant Chronic Ischemic Heart Disease, and/or Heart Failure - reCardial pilot study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00026136

Enrollment

Registered

2021-08-23

Start date

2021-10-18

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I10 I25 I50

Interventions

Group 1: Intervention group: reCardial-app in addition to standard care. Participants receive access to the reCardial app for 12 weeks. The smartphone application reCardial is a self management tool

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: the patient’s informed consent; being at least 18 years old; the ability to read and understand the German language; at least one diagnosis of hypertension (ICD-10: I10) with antihypertensive medication; owning a smartphone and being able to use it

Exclusion criteria

Exclusion criteria: having had an acute cardiovascular event (e.g., a myocardial infarction) within the previous four weeks; pregnancy; active psychosis or severe dementia (according to the instructions for use of reCardial app); prior use of reCardial app; simultaneous participation in another study

Design outcomes

Primary

Measure	Time frame
At baseline (pre-intervention), as well as at 12-week follow-up (post-intervention) all study participants will receive an online questionnaire. In line with the intended purpose of reCardial as a medical device, therapy guideline adherence after 12 weeks will be the primary endpoint. It will be assessed using the Self-Care of Hypertension Inventory (SC-HI) - Section A (Self-care Maintenance). The score is standardized from 0 to 100.	—

Measure

Time frame

At baseline (pre-intervention), as well as at 12-week follow-up (post-intervention) all study participants will receive an online questionnaire. In line with the intended purpose of reCardial as a medical device, therapy guideline adherence after 12 weeks will be the primary endpoint. It will be assessed using the Self-Care of Hypertension Inventory (SC-HI) - Section A (Self-care Maintenance). The score is standardized from 0 to 100.

—

Secondary

Measure	Time frame
All secondary endpoints will be collected with an online questionnaire completed by the patients at baseline (pre-intervention), as well as at 12-week follow-up (post-intervention). The online questionnaires include the following validated instruments for patient-reported outcomes: Self-Efficacy (Self-Care of Hypertension Inventory - Section C (Self-Management)), and Physical Activity (short version of the International Physical Activity Questionnaire (IPAQ-S)).	—

Measure

Time frame

All secondary endpoints will be collected with an online questionnaire completed by the patients at baseline (pre-intervention), as well as at 12-week follow-up (post-intervention). The online questionnaires include the following validated instruments for patient-reported outcomes: Self-Efficacy (Self-Care of Hypertension Inventory - Section C (Self-Management)), and Physical Activity (short version of the International Physical Activity Questionnaire (IPAQ-S)).

—

Countries

Germany

Contacts

Public ContactAndreas Fach

apprevent GmbH

a.fach@apprevent.com+49 421 691079 281

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026